Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.30 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672521 | 1.00 | KCNA3 (0.31) | KCNA3XBP1TDP1HTR1AADRA1D | |
| SCHEMBL23672523 | 1.00 | KCNA3 (0.31) | KCNA3XBP1TDP1HTR1AADRA1D | |
| SCHEMBL29501723 | 0.92 | MET (0.33) | KCNA3HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29501780 | 0.92 | TP53 (0.34) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23680929 | 0.92 | MET (0.33) | KCNA3HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23680928 | 0.92 | TP53 (0.34) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29501726 | 0.92 | HTR1A (0.38) | KCNA3HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23680921 | 0.92 | HTR1A (0.38) | KCNA3HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23680945 | 0.89 | EGFR (0.34) | KCNA3TDP1HTR1AADRA1DADRA1A | |
| SCHEMBL29501721 | 0.89 | EGFR (0.34) | KCNA3TDP1HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710429-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| US-11291205-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291205-B2 | Microbiocidal picolinamide derivatives | CASP2, CASP1, MSR1 | KCNA3 1289/4885XBP1 4089/4885TDP1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.